Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM).

Abstract

4562 Background: To further examine preclinical (Uehara, JNCI 2003) and clinical (Mathew, JCO 2004) evidence that the platelet-derived growth factor receptor (PDGFR) inhibitor, Imatinib, may modulate taxane activity in AIPC with BM, a randomized trial was conducted. METHODS 144 men with progressive AIPC with BM, no prior taxane, ECOG Performance Score (PS… (More)

Topics

Cite this paper

@article{Mathew2006PreliminaryRO, title={Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM).}, author={Preethy Joseph Mathew and Peter F. Thall and M. M. Johnson and William Oh and Anthony A Meluch and M. J. Morris and P. Brunny Troncoso and Cora D Bucana and Ingrid Fidler and C. J. Logothetis}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={4562} }